Showing 1-10 of about 14 articles.
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL
NEW YORK, April 30, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced additional details relating to the analysis presented by the Global Primary Biliary Cirrhosis Study Group (Study Group) at the annual meeting of the European Association for the Study of the Liver (EASL) held in Amsterdam on April 24-28, 2013. The Study Group presented an analysis of data from over 2,100 primary biliary cirrhosis (PBC) patients, among whom 981 patients met Intercept's ongoing Phase 3 POISE trial entry criteria at the time they initiated ursodiol therapy of having an alkaline phosphatase (ALP) level exceeding 1.67 times upper limit normal (ULN) and/or an abnormal bilirubin level. The analysis of this cohort of patients from the Study Group further substantiates the primary endpoint used in POISE as being strongly predictive of adverse clinical outcomes such as liver transplant and death in PBC patients.
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals to Present at Upcoming Healthcare Conferences
NEW YORK, April 25, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present at the following investor conferences in May:
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals Announces Upcoming EASL Presentation
NEW YORK, April 8, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced that an analysis by the Global Primary Biliary Cirrhosis (PBC) Study Group (also known as the PBC Supergroup) confirms that the endpoint used by Intercept in its ongoing Phase 3 POISE trial is strongly predictive of adverse clinical outcomes in PBC patients. The analysis reflects data from more than 2,100 patients. An abstract from the group will be presented at the annual meeting of the European Association for the Study of the Liver (EASL) taking place April 24-28, 2013 in Amsterdam.
Intercept Pharmaceuticals
Intercept Pharmaceuticals to Host 2012 Fourth Quarter and Full Year Financial Results Conference Call on March 18
NEW YORK, March 12, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it will report 2012 fourth quarter and full year financial results after the NASDAQ Market closes on Monday, March 18, 2013. Intercept management will conduct a conference call and audio webcast to discuss these results as well as provide a general business update at 5:30 p.m. EDT on the same day.
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals Appoints Daniel Regan as Chief Commercial Officer
NEW YORK, March 4, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the appointment of Daniel P. Regan to the newly created position of Chief Commercial Officer. Mr. Regan is a seasoned commercial executive bringing more than 20 years of pharmaceutical and biotechnology industry experience to the company.
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals to Present at the Cowen and Company 33rd Annual Healthcare Conference
NEW YORK, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present a company overview at the Cowen and Company 33rd Annual Health Care Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts, on March 4, 2013 at 4:10-4:40 p.m. Eastern time.
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals to Present at Leerink Swann 2013 Global Healthcare Conference
NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present a company overview at the Leerink Swann 2013 Global Healthcare Conference in New York on February 14, 2013 at 3:30 p.m. Eastern time.
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals Announces Completion of Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial
NEW YORK, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it has completed enrollment in POISE, its pivotal Phase 3 clinical trial of obeticholic acid (OCA) in primary biliary cirrhosis (PBC). Results from the 12-month double-blind portion of POISE are anticipated to be available in the second quarter of 2014 and, if successful, will be used to seek regulatory approval of OCA, a first-in-class FXR agonist, as a second line treatment in PBC. By enrolling 218 patients at 59 centers in 13 countries, Intercept exceeded its targeted number of patients and completed enrollment in POISE faster than originally projected.
Showing 1-10 of about 14 articles.